Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NSA1
UPID:
FGF21_HUMAN
Alternative names:
-
Alternative UPACC:
Q9NSA1; Q8N683
Background:
Fibroblast growth factor 21 (FGF21) plays a pivotal role in glucose metabolism, primarily by enhancing glucose uptake in adipocytes through upregulation of glucose transporter SLC2A1/GLUT1. Its activity is contingent upon the presence of KLB, highlighting a specific pathway for its function. FGF21's influence extends to systemic glucose homeostasis and insulin sensitivity, marking it as a key player in metabolic regulation.
Therapeutic significance:
Understanding the role of Fibroblast growth factor 21 could open doors to potential therapeutic strategies. Its direct involvement in glucose metabolism and insulin sensitivity positions FGF21 as a promising target for the development of treatments aimed at metabolic disorders, including diabetes and obesity.